获取途径

作者

Xue Qiao, Bingwei Liu, Silin Mu, Chunhong Xu, Penglai Yang, Lishuang Yang, Liang Li, Shouhua Chen, Meng Wang, Hanhan Chen, Hongzhi Chen, Jingwei Li

作者单位

Affiliations ¹ First Clinical Medical College, Shandong University of TCM, Jinan 250014, China. ² College of TCM, Shandong University of TCM. ³ Breast and Thyroid Surgery, Weifang Hospital of TCM. ⁴ First Department of Surgery, Zaozhuang Hospital of TCM. ⁵ Breast and Thyroid Surgery, Zibo Central Hospital. ⁶ Breast Surgery, First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital. ⁷ Institute of Resource for Chinese Materia Medica, Shandong Academy of Chinese Medicine. ⁸ Breast and Thyroid Surgery, Affiliated Hospital of Shandong University of TCM, Jinan 25001 ⁹ College of Rehabilitation Medicine, Shandong University of TCM.

刊名

Zhongguo zhen jiu = Chinese acupuncture & moxibustion

年份

2024

卷号

Vol.44 No.5

页码

513-520

ISSN

0255-2930

关键词

Hashimoto's thyroiditis (HT) acupoint application randomized controlled trial (RCT) thyroglobulin antibody (TgAb) thyroid peroxidase antibody (TPOAb).

摘要

Objective: To observe the clinical efficacy and safety of acupoint application for Hashimoto's thyroiditis with liver-qi stagnation. Methods: One hundred and fifty patients of HT with liver-qi stagnation were randomly divided into an acupoint application group and a control group . Based on the health education combined with conventional western medicine treatment, the patients in the acupoint application group were treated with acupoint application, while the patients in the control group wer...更多

Objective: To observe the clinical efficacy and safety of acupoint application for Hashimoto's thyroiditis with liver-qi stagnation. Methods: One hundred and fifty patients of HT with liver-qi stagnation were randomly divided into an acupoint application group and a control group . Based on the health education combined with conventional western medicine treatment, the patients in the acupoint application group were treated with acupoint application, while the patients in the control group were treated with placebo acupoint application. Shenque , bilateral Yongquan , Yeshi, and ashi point were selected in both groups, with Yeshi treated once a week and the remaining acupoints treated every other day, for a total of 4 weeks. The serum levels of thyroglobulin antibody , thyroid peroxidase antibody , free triiodothyronine , free thyroxine , and thyroid-stimulating hormone , as well as the thickness of thyroid left lobe, right lobe, and isthmus, TCM symptom score, hospital anxiety and depression scale score, and MOS 36-item short form health survey score were compared between the two groups before and after treatment. Adverse reactions in both groups were observed. Results: Compared with before treatment, in the acupoint application group, the serum levels of TgAb and TPOAb were reduced after treatment . There was no statistically significant difference in the above indexes between the two groups . The incidence of adverse reactions in the acupoint application group and the control group was 20.0% and 10.7% respectively, with skin allergy being the main adverse reaction. Conclusion: Acupoint application could reduce the serum levels of TgAb and TPOAb in patients of HT with liver-qi stagnation, alleviate thyroid enlargement, improve TCM symptoms and anxiety, and improve quality of life, with safe and reliable clinical efficacy.收起

文献类型

期刊